As of 2024-12-14, the Intrinsic Value of Beam Therapeutics Inc (BEAM) is
20,008.31 USD. This BEAM valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y).
With the current market price of 27.93 USD, the upside of Beam Therapeutics Inc is
71,537.30%.
The range of the Intrinsic Value is 16,769.63 - 24,689.83 USD
20,008.31 USD
Intrinsic Value
BEAM Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(257,622.22) - (90,135.08) |
(132,783.48) |
-475515.3% |
| DCF (Growth 10y) |
(904,793.16) - (2,781,949.19) |
(1,382,272.67) |
-4949160.8% |
| DCF (EBITDA 5y) |
16,769.63 - 24,689.83 |
20,008.31 |
71537.3% |
| DCF (EBITDA 10y) |
279,526.99 - 442,536.47 |
346,243.44 |
1239582.9% |
| Fair Value |
-8.67 - -8.67 |
-8.67 |
-131.04% |
| P/E |
(47.79) - (52.85) |
(46.64) |
-267.0% |
| EV/EBITDA |
(21.85) - 3,210.72 |
1,165.71 |
4073.7% |
| EPV |
(28.30) - (37.95) |
(33.12) |
-218.6% |
| DDM - Stable |
(18.90) - (71.23) |
(45.06) |
-261.3% |
| DDM - Multi |
(100.76) - (294.93) |
(150.18) |
-637.7% |
BEAM Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
2,312.88 |
| Beta |
2.35 |
| Outstanding shares (mil) |
82.81 |
| Enterprise Value (mil) |
2,082.68 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.31% |
| Cost of Debt |
7.25% |
| WACC |
8.31% |